MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
10.72
+0.82
+8.28%
Pre Market: 10.72 0 0.00% 04:01 10/29 EDT
OPEN
9.74
PREV CLOSE
9.90
HIGH
10.74
LOW
9.67
VOLUME
115
TURNOVER
0
52 WEEK HIGH
13.90
52 WEEK LOW
7.36
MARKET CAP
953.66M
P/E (TTM)
-3.1885
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KURA last week (1019-1023)?
Weekly Report · 3d ago
Weekly Report: what happened at KURA last week (1012-1016)?
Weekly Report · 10/19 09:24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ramsay Health Care (OtherRMSYF), PTC Therapeutics (PTCT) and Kura Oncology (KURA)
TipRanks · 10/14 12:30
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Alnylam Pharma (ALNY) and Kura Oncology (KURA)
TipRanks · 10/14 11:10
Caspian Therapeutics, Kura Oncology Outline Development Path For Diabetes Candidate KO-7246
NASDAQ · 10/13 14:30
Kura Oncology, Caspian outline KO-7246 development strategy in diabetes
TipRanks · 10/13 13:21
Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseases
Benzinga · 10/13 11:31
Weekly Report: what happened at KURA last week (1005-1009)?
Weekly Report · 10/12 09:26
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.